Washington, D.C. 20549
The information required in the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
CUSIP No. 76135L101
1. Names
of Reporting Person: George F Tidmarsh
I.R.S. Identification Nos. of above persons (entities only):
2. Check
the Appropriate Box if a Member of a Group (See Instructions)
(a)
☐
(b)
☒
3. SEC
Use Only:
4. Source
of Funds (See Instruction):
PF
5. Check
if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or (e):
☐
6. Citizenship
or Place of Organization:
United States of America
Number of Shares Beneficially by Owned by Each Reporting Person With:
7
|
Sole Voting Power:
|
2,013,335(1)
|
|
|
|
8
|
Shared Voting Power:
|
-0-
|
|
|
|
9
|
Sole Dispositive Power:
|
2,013,335(1)
|
|
|
|
10
|
Shared Dispositive Power:
|
-0-
|
11. Aggregate Amount
Beneficially Owned by Each Reporting Person: 2,013,335(1)
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):
☐
13.Percent of Class
Represented by Amount in Row (11):
14.1%
14.Type of Reporting
Person (See Instructions):
IN
|
(1)
|
Consists of (i) 1,523,335 shares of Common Stock held by George
Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust, (ii) 447,156 shares of Common Stock held directly by Dr. Tidmarsh,
and (iii) 42,844 shares of Common stock from Rollover RSU’s vesting and issuable within 60 days to Dr. Tidmarsh.
|
ITEM 1. SECURITY
AND ISSUER
Shares of Common Stock, par value $0.001 per share
ITEM 2. IDENTITY
AND BACKGROUND
(a)
Name of Persons filing this Statement:
George F Tidmarsh
(b)
Residence or Business Address:
Revelation Biosciences, Inc.
4660 La Jolla Village Drive, Suite 100
San Diego, California 92122
(c)
Present Principal Occupation and Employment:
The Reporting Person is a physician and scientist.
He also is currently the non-executive Chairman of the Board of Directors of the Company.
(d)
Criminal Convictions:
None
of the Reporting Persons have been charged or convicted in a criminal proceeding during the last five years.
(e)
Civil Proceedings:
None of the Reporting Persons have been a party to a civil proceeding
of a judicial or administrative body of competent jurisdiction during the last five years where such person, as result of such proceeding,
was or became subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject
to, federal or state securities laws or finding any violation with respect to such law.
(f)
State of Incorporation/Organization/Citizenship: United States
ITEM 3. SOURCE
AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Personal funds
ITEM 4. PURPOSE
OF TRANSACTION
The Reporting Person is a founder of Revelation Biosciences, Inc. (“Old
Revelation”), and received 1,813,986 of his shares in the Company as a result of the merger (the “Merger”) between Old
Revelation and Petra Acquisition, Inc., which changed its name to Revelation Biosciences, Inc. (“New Revelation” or the “Company”).
Prior to the closing of the Merger, the Reporting Person entered into a backstop agreement with the Company pursuant to which he acquired
64,545 of his shares to facilitate the completion of the Merger. The balance of his shares were acquired for investment purposes.
ITEM 5. INTEREST
IN SECURITIES OF THE ISSUER
The response to Item 4 is incorporated herein by reference.
ITEM 6. CONTRACTS,
ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER
The Reporting Person serves as non-executive Chairman of the Board of the
Company and pursuant to the Certificate of Incorporation he serves on the Board until the 2023 Annual Meeting of Stockholders. He also
serves on the Audit and Compensation Committees of the Company. There are no other contracts of understandings or understandings with
respect to his ownership or control of the Company except the Reporting Person is subject to a Lock-Up agreement which restricts his ability
to sell shares of the Company until July 9, 2022. The Reporting Person is also subject to a Right of First Refusal Agreement with AXA
IM PRIME IMPACT MASTER FUND I SCA SICAV-RAIF with respect to 170,325 of his shares of Company common stock until December 31, 2022.
ITEM 7. MATERIAL
TO BE FILED AS EXHIBITS
SIGNATURE
After reasonable inquiry and to the best of my
knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2022
|
/s/
George F Tidmarsh
|
|
Name: George F Tidmarsh
|
5